CBER’s Goodman Eyes Tissue, Blood Test Innovation Through Post-9/11 Lens
This article was originally published in The Gray Sheet
Development of tests to screen blood and tissues for multiple pathogens would help safeguard public health and national security, Center for Biologics Evaluation & Research Director Jesse Goodman, MD/MPH, stresses in an Aug. 19 New England Journal of Medicine editorial
You may also be interested in...
FDA's tissue donor eligibility final rule will go into effect May 25, 2005, one year after its publication in the Federal Register
FDA's "critical path" initiative to help streamline R&D costs and product development schedules is positioning the agency to eventually seek grant-making authority from Congress
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.